Innovent Biologics (HK:1801) has released an update.
Innovent Biologics saw a robust rise in its third-quarter 2024 revenue, surpassing RMB2.3 billion, marking a significant 40% increase from the previous year. The company attributes this growth to the strong performance of its oncology products, especially TYVYT, and the successful market launch of Dupert for lung cancer treatment. Innovent continues to strengthen its position in the biomedicine sector with a diverse product portfolio and strategic market penetration efforts.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
